Does PALBOCICLIB Cause Breast cancer recurrent? 126 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 126 reports of Breast cancer recurrent have been filed in association with PALBOCICLIB (Ibrance). This represents 0.1% of all adverse event reports for PALBOCICLIB.
126
Reports of Breast cancer recurrent with PALBOCICLIB
0.1%
of all PALBOCICLIB reports
6
Deaths
16
Hospitalizations
How Dangerous Is Breast cancer recurrent From PALBOCICLIB?
Of the 126 reports, 6 (4.8%) resulted in death, 16 (12.7%) required hospitalization, and 5 (4.0%) were considered life-threatening.
Is Breast cancer recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 126 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Breast cancer recurrent?
LETROZOLE (285)
TRASTUZUMAB (268)
TAMOXIFEN (260)
FULVESTRANT (219)
ANASTROZOLE (214)
CYCLOPHOSPHAMIDE (182)
RIBOCICLIB (180)
PACLITAXEL (151)
DOCETAXEL (138)
DOXORUBICIN (114)
Which PALBOCICLIB Alternatives Have Lower Breast cancer recurrent Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID